We have shown that the immunomodulatory effects of trastuzumab and antiangiogenic effects of bevacizumab are complementary and can provide a novel therapeutic strategy for HER2-expressing chemoresistant SCLC. The gene discussed is ERBB2; the disease is small cell lung carcinoma.